Comprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three Subtypes

Four gene expression subtypes of high-grade serous ovarian cancer (HGSC) have been previously described. In these early studies, a fraction of samples that did not fit well into the four subtype classifications were excluded. Therefore, we sought to systematically determine the concordance of transcriptomic HGSC subtypes across populations without removing any samples. We created a bioinformatics pipeline to independently cluster the five largest mRNA expression datasets using k-means and nonnegative matrix factorization (NMF). We summarized differential expression patterns to compare clusters across studies. While previous studies reported four subtypes, our cross-population comparison does not support four. Because these results contrast with previous reports, we attempted to reproduce analyses performed in those studies. Our results suggest that early results favoring four subtypes may have been driven by the inclusion of serous borderline tumors. In summary, our analysis suggests that either two or three, but not four, gene expression subtypes are most consistent across datasets.

[1]  R. Sokal,et al.  THE COMPARISON OF DENDROGRAMS BY OBJECTIVE METHODS , 1962 .

[2]  L. Rasmussen,et al.  Functional Genomics , 2012, Methods in Molecular Biology.

[3]  C. Planey,et al.  CoINcIDE: A framework for discovery of patient subtypes across multiple datasets , 2016, Genome Medicine.

[4]  Carl Boettiger,et al.  An introduction to Docker for reproducible research , 2014, OPSR.

[5]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[6]  E. Goode,et al.  Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. , 2014, Journal of the National Cancer Institute.

[7]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Wing H Wong,et al.  Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. , 2005, Cancer research.

[9]  Pablo Tamayo,et al.  Metagenes and molecular pattern discovery using matrix factorization , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[11]  I. Shih,et al.  Ovarian Low-grade and High-grade Serous Carcinoma: Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems , 2009, Advances in anatomic pathology.

[12]  Anne-Marie Mes-Masson,et al.  Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling , 2005, Oncogene.

[13]  Tatsuhiko Tsunoda,et al.  High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway , 2012, Clinical Cancer Research.

[14]  S. Silverberg Histopathologic grading of ovarian carcinoma: a review and proposal. , 2000, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[15]  R. Soslow,et al.  Histologic subtypes of ovarian carcinoma: an overview. , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[16]  S. Blagden,et al.  Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer , 2015, Front. Oncol..

[17]  Benjamin Haibe-Kains,et al.  curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome , 2013, Database J. Biol. Databases Curation.

[18]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[20]  K. Cibulskis,et al.  Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. , 2012, The Journal of clinical investigation.

[21]  Francesmary Modugno,et al.  Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[22]  Ling-Zhi Wang,et al.  Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer , 2013, EMBO molecular medicine.

[23]  Ie-Ming Shih,et al.  The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory , 2010, The American journal of surgical pathology.

[24]  Benjamin A. Logsdon,et al.  Extracting a low-dimensional description of multiple gene expression datasets reveals a potential driver for tumor-associated stroma in ovarian cancer , 2016, bioRxiv.

[25]  Laurent Ozbun,et al.  A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. , 2008, Cancer research.

[26]  K. Ickstadt,et al.  Identifying Interesting Genes with siggenes , 2006 .